Evaluating the effectiveness and safety of a combination medication for cholesterol management

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the efficacy and safety of a fixed-dose combination of Pitavastatin and Ezetimibe in patients with primary hypercholesterolemia or mixed dyslipidemia under real-world conditions. Participants will be those currently taking statins or a combination of statins and Ezetimibe, who require a change in their medication regimen. The study will observe the outcomes of this combination therapy to determine its effectiveness in managing cholesterol levels.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Those who taking statins or statins and ezetimibe in addition to dietary and exercise therapy for primary hypercholesterolemia or mixed hyperlipidemia
* Those who are judged to need administration of a fixed-dose combination of pitavastatin/ezetimibe for change of statin's formulation or change of statin's dose, addition of ezetimibe

Exclusion Criteria:

* Those who are taking a fixed-dose combination of pitavastatin/ezetimibe at study enrollment
* Those with hypersensitivity reactions or relevant medical history to pitavastatin or ezetimibe
* Those who have been administered an investigational product within 12 weeks of the enrollment date or are planning to participate in another clinical trial during this study participation period.

Where it's running

• Ewha Womans University Seoul Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Shin-young Oh
• Email: syoh@boryung.co.kr
• Phone: +82-2-708-8000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MWX203: a medicine for mixed dyslipidemia given alone or with Inclisiran

  This phase 2 study tests MWX203 alone or with Inclisiran in adults with mixed dyslipidemia who don’t reach lipid goals on statins.

  Recruiting Phase 2 Shanghai Minwei Biotechnology Co., Ltd · Beijing, Beijing Municipality · NCT07803822

• Obicetrapib vs. bempedoic acid for high-risk high cholesterol patients

  This phase 3 study tests whether obicetrapib can lower LDL-C more than bempedoic acid in adults with primary non-familial hypercholesterolemia or mixed dyslipidemia who still have high LDL-C despite maximum tolerated therapy.

  Recruiting Phase 3 A. Menarini International Licensing S.A. · Stockton-on-Tees · NCT07614958

• Bempedoic Acid With Ezetiimibe in Adults with High Cholesterol or Mixed Dyslipidemia

  This study tests bempedoic acid alone or with ezetimibe in real-world adults with primary hypercholesterolemia or mixed dyslipidemia to see how safe and effective it is in routine care.

  Recruiting at 38 sites Daiichi Sankyo · Belo Horizonte and 37 other locations · NCT07206472

• Comparing the effects of two medications on healthy individuals

  This study tests how two medications work in healthy people to see if one is safer or more effective than the other.

  Recruiting Phase 1 Addpharma Inc. · Seoul · NCT06932705

• Evaluating HST101 for lowering cholesterol in Chinese patients

  This study is testing if a new drug called HST101 can lower cholesterol levels in Chinese patients who have high cholesterol and are at risk for heart disease.

  Recruiting at 17 sites Phase 3 Hasten Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 17 other locations · NCT06568471

• Evaluating the effectiveness and safety of AD-218 for mixed dyslipidemia

  This study is testing if a new drug called AD-218 can help people with mixed dyslipidemia improve their cholesterol levels and overall health.

  Recruiting Phase 3 Addpharma Inc. · Daegu, Nam-gu · NCT05400317

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.